期刊文献+

利奈唑胺与万古霉素治疗耐甲氧西林金黄色葡萄球菌性呼吸机相关肺炎的临床研究 被引量:3

下载PDF
导出
摘要 比较利奈唑胺与万古霉素在治疗患者耐甲氧西林金黄色葡萄球菌(MR-SA)所致呼吸机相关肺炎(VAP)的临床效果。方法:分析2009年1月~2011年6月痰菌培养为MRSA的呼吸机相关肺炎32例次,分别接受利奈唑胺和万古霉素治疗,分析其药敏结果、疗程、不良反应及预后。结果:①药敏试验MRSA对利奈唑胺及万古霉素敏感率均100%;②临床有效率:利奈唑胺组(60%)明显高于万古霉素组(47.0%),P<0.05;③痰菌清除率:利奈唑胺组(73.3%)明显高于万古霉素组(58.8%);④30天死亡率两组间无显著差异。⑤不良反应发生率两组之间无显著差异。结论:对MRSA所致呼吸机相关肺炎,利奈唑胺在临床疗效、痰菌清除率等方面明显优于万古霉素,不良反应两者之间无明显差异。
作者 朱金伟
出处 《中国社区医师(医学专业)》 2012年第4期46-47,共2页
  • 相关文献

参考文献4

二级参考文献31

  • 1卫林英,段兴民.Meta分析在科学研究中的应用与展望[J].生产力研究,2006(6):144-146. 被引量:10
  • 2朱德妹,汪复,张婴元.2005年上海地区细菌耐药性监测[J].中国感染与化疗杂志,2006,6(6):371-376. 被引量:82
  • 3Keller MH. Epidemiology and risk factors for nosocomial pneumonia clin. Chest Med, 1999,20:653 - 670.
  • 4Mathews PJ, Mathews LM. Reducing the risks of ventilator associated infections. Dimens Crit Care Nurs,2000,19 : 17 - 21.
  • 5Linden P.Ues of linezolid for gram-positive infections[J].Infec Med,2002,19(1):25 32.
  • 6Sisson TL,Jungnluth GL,Hopkins NK.Age and sex ef-fects on the pharmacokinetics of linezolid[J].Eur J Clin Pharmacol,2002,57(11):793-797.
  • 7Diekmea DJ,Jones RN.Oxazolidinone antibiotics[J].Lancet,2001,358(9297):1975-1982.
  • 8Fines M,Leclercq R.Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors[J].J Antimicrob Chemother,2000,45(4):797-802.
  • 9Gander S,Haywark K,Finch R.An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in uitro pharmacolinetic mode[J].J Antimicrob Chemother,2002,49 (2):301-308.
  • 10Cazzola M,Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections[J].Pulm Pharmacol Ther,2001,14(5):367.

共引文献106

同被引文献36

  • 1张永信.解读抗菌药物临床应用指导原则[J].上海医药,2005,26(2):62-63. 被引量:21
  • 2王从容.抗菌新药——利奈唑胺[J].中国医院药学杂志,2006,26(5):614-616. 被引量:23
  • 3Patel U, Yah YP, Hobbs FW Jr, et al. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation [ J ]. J Biol Chem,2001,276(40) :37199-37205.
  • 4Linden P. Ues of linezolid for gram-positive infections [ J ]. Infec Med, 2002,19( 1 ) :25-32.
  • 5Sisson TL,Jungnluth GL,Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid [ J ]. Eur J Clin Pharmacol, 2002,57 ( 11 ) :793-797.
  • 6Diekmea DJ, Jones RN. Oxazolidinone antibiotics [ J ]. Lancet, 2001, 358 (9297) : 1975-1982.
  • 7Fines M, Leclereq R. Activity of linezolid against Gram-positive cocci Possessing genes conferring resistance to protein synthesis in hibitors [ J ]. Antimicrob Chemother, 2000,45 ( 4 ) : 797-802.
  • 8Moellering RC Jr. Linezolid: the first oxazolidinone antimicrobial [J]. Ann Intern Med,2003,138(2) :135-142.
  • 9Meagher AK, Forrest A,Rayner CA, et al. Population pharmaeokinetics of linezolid in patients treated in compassionate-use program [J]. Antimicrob Agents Chemocher,2003,47(2) :548-553.
  • 10Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-asoociated pneumonia: retrospective analysis of two double-blind atudies comparing linezolid with vancomycin [ J ]. Intesive Care Med,2004,30 ( 3 ) : 343-346.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部